Cargando…
Access to benznidazole for Chagas disease in the United States—Cautious optimism?
Drugs for neglected tropical diseases (NTD) are being excessively priced in the United States. Benznidazole, the first-line drug for Chagas disease, may become approved by the Food and Drug Administration (FDA) and manufactured by a private company in the US, thus placing it at risk of similar prici...
Autores principales: | Alpern, Jonathan D., Lopez-Velez, Rogelio, Stauffer, William M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5598921/ https://www.ncbi.nlm.nih.gov/pubmed/28910299 http://dx.doi.org/10.1371/journal.pntd.0005794 |
Ejemplares similares
-
Access to Chagas disease treatment in the United States after the regulatory approval of benznidazole
por: Yoshioka, Kota, et al.
Publicado: (2020) -
Chagas Disease in Spain: Need for Further Public Health Measures
por: Navarro, Miriam, et al.
Publicado: (2012) -
Cautious Optimism Regarding Early Transcatheter Aortic Valve Replacement
por: Abdelfattah, Omar M., et al.
Publicado: (2022) -
Broken drug markets in infectious diseases: Opportunities outside the private sector?
por: Alpern, Jonathan D., et al.
Publicado: (2019) -
Congenital Chagas Disease in the United States: The Effect of Commercially Priced Benznidazole on Costs and Benefits of Maternal Screening
por: Perez-Zetune, Victoria, et al.
Publicado: (2020)